Results 341 to 350 of about 1,311,555 (408)
Lymphocyte subset reconstitution and clinical outcomes following haploidentical hematopoietic stem cell transplantation. [PDF]
Jiang P +15 more
europepmc +1 more source
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor +12 more
wiley +1 more source
Day zero of autologous cryopreserved hematopoietic stem cell transplantation: microcosting of care provided by senior nurses. [PDF]
Nunes VAG, Lima AFC.
europepmc +1 more source
The Role of Lnk Adaptor Protein in Hematopoietic Stem Cell Genome Stability and Self-Renewal
Joanna Balcerek
openalex +1 more source
Measurable residual disease monitoring after hematopoietic stem cell transplantation. [PDF]
Shin S.
europepmc +1 more source
Allogeneic Hematopoietic Stem Cell Transplantation as a Therapeutic Approach for Hereditary Diseases. [PDF]
Nagieva S, Smirnikhina S.
europepmc +1 more source
Novel oral chidamide and valganciclovir regimen for EBV-PTLD post-hematopoietic stem cell transplantation: A case report. [PDF]
Wu Y, Zhong Z, Mei H.
europepmc +1 more source
MRP1: A TARGET FOR HEMATOPOIETIC STEM CELL DISEASES
Cassandra J. Reiling
openalex +1 more source

